Your session is about to expire
← Back to Search
Edwards FORMA Tricuspid Transcatheter Repair System for Tricuspid Valve Regurgitation
Study Summary
This trial is testing a new treatment for tricuspid valve disease and will help researchers understand how safe and effective it is.
- Tricuspid Valve Regurgitation
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the principal aim of this investigation?
"The primary outcome of this research project, assessed over a one-month period, is to measure the Major Adverse Event Rate. Secondary objectives consist of examining Procedure Success (device success and reduction in tricuspid regurgitation), Device Deployment rate, as well as assessing how many patients achieved successful device deployment followed by retrieval from the cardiac catheterisation laboratory."
Is there capacity for enrollment in this experiment?
"According to clinicaltrials.gov, recruitment for this trial has ceased. It was first posted on December 1st 2015 and last updated on the 9th of December 2021. Although this specific study is not recruiting anymore, 40 other medical trials are currently in search of participants."
Are there any U.S.-based locations that have initiated this research?
"7 recruiting centres are available for this trial, including the prestigious Lankenau Medical Center in Wynnewood, Emory University Hospital in Atlanta and Cedars-Sinai Medical Center in Los Angeles. Additionally, there are 4 other sites located across America."
Share this study with friends
Copy Link
Messenger